Intensity-Modulated Radiotherapy-Based Reirradiation for Head and Neck Cancer: A Multi-institutional Study by Korean Radiation Oncology Group (KROG 1707)

Jeongshim Lee; Tae Hyung Kim; Yeon-Sil Kim; Myungsoo Kim; Jae Won Park; Sung Hyun Kim; Hyun Ju Kim; Chang Geol Lee

doi:10.4143/crt.2020.310

Articles

Page Path: HOME > Cancer Res Treat > Volume 52(4); 2020 > Article

Original Article Head/neck cancer Intensity-Modulated Radiotherapy-Based Reirradiation for Head and Neck Cancer: A Multi-institutional Study by Korean Radiation Oncology Group (KROG 1707): Jeongshim Lee, MD¹, Tae Hyung Kim, MD², Yeon-Sil Kim, MD, PhD³, Myungsoo Kim, MD, PhD⁴, Jae Won Park, MD, PhD⁵, Sung Hyun Kim, MD⁶, Hyun Ju Kim, MD⁷, Chang Geol Lee, MD, PhD^2,; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2020;52(4):1031-1040.
DOI: https://doi.org/10.4143/crt.2020.310
Published online: July 7, 2020

¹Department of Radiation Oncology, Inha University Hospital, Inha University College of Medicine, Incheon, Korea

²Department of Radiation Oncology, Yonsei University College of Medicine, Seoul, Korea

³Department of Radiation Oncology, St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

⁴Department of Radiation Oncology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

⁵Department of Radiation Oncology, Yeungnam University Medical Center, Yeungnam University College of Medicine, Daegu, Korea

⁶Department of Radiation Oncology, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju, Korea

⁷Department of Radiation Oncology, Gachon University Gil Medical Center, Incheon, Korea

Correspondence: Chang Geol Lee, MD, PhD Department of Radiation Oncology, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea
Tel: 82-2-2228-8114 Fax: 82-2-312-9033 E-mail: cglee1023@yuhs.ac

• Received: April 14, 2020 • Accepted: July 6, 2020

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

7,950 Views
185 Download
15 Web of Science
5 Crossref
16 Scopus

prev next

Full Article

Download PDF

Abstract

Purpose
The benefits of reirradiation for head and neck cancer (HNC) have not been determined. This study evaluated the efficacy of reirradiation using intensity-modulated radiotherapy (IMRT) for recurrent or second primary HNC (RSPHNC) and identified subgroups for whom reirradiation for RSPHNC is beneficial.
Materials and Methods
A total of 118 patients from seven Korean institutions with RSPHNC who underwent IMRT-based reirradiation between 2006 and 2015 were evaluated through retrospective review of medical records. We assessed overall survival (OS) and local control (LC) within the radiotherapy (RT) field following IMRT-based reirradiation. Additionally, the OS curve according to the recursive partitioning analysis (RPA) suggested by the Multi-Institution Reirradiation (MIRI) Collaborative was determined.
Results
At a median follow-up period of 18.5 months, OS at 2 years was 43.1%. In multivariate analysis, primary subsite, recurrent tumor size, interval between RT courses, and salvage surgery were associated with OS. With regard to the MIRI RPA model, the class I subgroup had a significantly higher OS than class II or III subgroups. LC at 2 years was 53.5%. Multivariate analyses revealed that both intervals between RT courses and salvage surgery were prognostic factors affecting LC. Grade 3 or more toxicity and grade 5 toxicity rates were 8.5% and 0.8%, respectively.
Conclusion
IMRT-based reirradiation was an effective therapeutic option for patients with RSPHNC, especially those with resectable tumors and a long interval between RT courses. Further, our patients' population validated the MIRI RPA classification by showing the difference of OS according to MIRI RPA class.
Key words: Head and neck neoplasm, Recurrence, Reirradiation, Intensity modulated radiotherapy

Introduction

Despite aggressive multidisciplinary management including radiotherapy (RT), up to half of patients with locally advanced head and neck cancer (HNC) experience locoregional recurrence [1-3]. Although surgery was the best salvage therapy option for such patients, only a few patients could be candidates for surgical resection due to unresectability or inoperability associated with poor performance functions and their comorbidities [4,5]. Thus, for these patients, reirradiation has been considered as a salvage therapy to improve outcomes, although the concern of severe toxicity following reirradiation has remained [6].

With the widespread adoption of conformal RT techniques such as intensity-modulated RT (IMRT) and volume-modulated arc therapy, the therapeutic ratio of reirradiation may have increased owing to the advanced technique using multiple small beamlets, which have an accurate target system for irregularly shaped tumors while simultaneously avoiding normal tissue [7,8]. Therefore, reirradiation in the modern advanced RT era has led to the expectation that the efficacy after reirradiation would be improved [9], and it has contributed to the frequent application of reirradiation using IMRT in clinical practice [10-12].

However, the efficacy of reirradiation in the IMRT era still remains unclear. In particular, difficulties associated with the selection of patients who would benefit from reirradiation and the potential for lethal toxicity following reirradiation are barriers to performing reirradiation. Therefore, we conducted a multi-institutional study to describe the efficacy of IMRT-based reirradiation for recurrent or second primary HNC (RSPHNC) and to identify prognostic factors for which the benefit of reirradiation appears favorable. We also sought to externally validate the recursive partitioning analysis (RPA) published by the Multi-Institution Reirradiation (MIRI) Collaborative [13].

Materials and Methods

1. Study design

We performed a multicenter, retrospective cohort study to assess the efficacy of IMRT-based reirradiation for HNC. The eligibility criteria were as follows: (1) adult patients (≥ 18 years) who had locoregional RSPHNC without distant metastasis (M0) based on histologic and/or radiographic evidence of progression of the disease treated with IMRT-based reirradiation from January 1, 2006, to December 31, 2015; (2) availability of a medical record related to the initial radiation dose; and (3) patients who previously received ≥ 40 Gy RT at the reirradiation site. Information on the patients’ clinicodemographic characteristics, tumor characteristics, and administered treatments was collected from their medical records. All institutions decided on re-irradiation for pati-ents with RSPHNC through each institution’s multidisciplinary discussion during a head and neck tumor conference, in which an otolaryngologist, radiation oncologist, medical oncologist, and radiologist participated. Finally, 118 patients from seven institutions with recurrent (n=109) or second primary (n=9) HNC who underwent IMRT-based reirradiation were analyzed.

2. Treatment outcomes and prognostic variables

The primary endpoint was 2-year overall survival (OS) rate, and the secondary endpoint was local control (LC) rate. OS period was calculated from the time of reirradiation for recurrence to the date of death from any cause, and freedom from local progression was defined as an absence of disease on histologic and radiographic evaluation from the reirradiation. The prognostic factors associated with OS and LC were as follows: age, sex, Karnofsky performance status, initial subsite, initial histology, surgery at recurrence, tumor size at recurrence, interval between RT courses, and organ dysfunction at reirradiation. In addition, we divided patients into prognostic subgroups using the RPA according to the interval between RT courses, resectability, and organ dysfunction defined by the MIRI Collaborative [13] and assessed OS by class. Additionally, the late toxicity following reirradiation was assessed by reviewing medical charts.

3. Statistical analysis

Actuarial estimates for OS and LC were calculated using the Kaplan-Meier methods. Log-rank test was used to compare risk factors affecting survival and LC estimates in univariate analysis. A Cox regression model was used to identify potential prognostic factors for OS and LC in univariate and multivariate analyses. All analyses were performed using IBM SPSS ver. 20.0 (IBM Corp., Armonk, NY).

4. Ethical statement

This study was approved by the institutional review board of each participating institution. The requirement for informed consent was waived. We carried out this research according to the principles expressed in the declaration of Helsinki.

Results

1. Patient and treatment characteristics

The median age when performing IMRT-based reirradiation was 59 years (range, 20 to 90 years). Of the total patients, 95 patients (80.5%) had squamous cell carcinoma and 82 patients (69.5%) showed stage III/IV at initial presentation. The approach to the RSPHNC consisted of surgery for 40.7% (n=48; R0 resection in 29 patients and R1 resection in 19 patients) and chemotherapy for 72.9% (n=86) of the patients. Fractionation of IMRT-based reirradiation was once daily for all patients. The treatment volume included focal field in 84.7%, which was defined by the gross tumor or surgical bed plus a margin of 0.5-1.0 cm, and radical field in 15.3%, encompassing the gross tumor or surgical bed with an elective high-risk area plus a margin of 0.5-1.0 cm. The median interval period between RT courses was 29.4 months (range, 2.6 to 293.4 months). The median initial RT total dose, IMRT-based reirradiation total dose, and cumulative RT dose were 66 Gy (range, 40.0 to 78.6 Gy), 59.4 Gy (range, 36.0 to 75.0 Gy), and 124.9 Gy (range, 90.0 to 146.3 Gy), respectively. With regard to RPA classes, class I, II, and III accounted for 21.2%, 75.4%, and 3.4%, respectively. The baseline characteristics of 118 patients from seven institutions are summarized in Table 1. Furthermore, the baseline characteristics according to each institution are shown in S1 Table.

2. Outcomes and prognostic factors

The median duration of follow-up after IMRT-based reirradiation was 18.5 months (range, 1.4 to 98.0 months). Twenty-nine patients (24.6%) remained alive at the time of the last observation. The median OS duration and 2-year OS rate were 20.1 months (range, 16.1 to 24.1 months) and 43.1%, respectively (Fig. 1). The Kaplan-Meier curve of factors related to OS after reirradiation identified primary subsites (p < 0.001) (Fig. 2A), RSPHNC tumor size (p < 0.001) (Fig. 2B), number of RSPHNC (p=0.041), interval between RT courses (p=0.007) (Fig. 2C), and performance of salvage surgery for RSPHNC (p=0.002) (Fig. 2D) as significant factors. In a multivariate stepwise Cox regression model analysis, primary subsites (non-hypopharynx/larynx/oral cavity vs. hypopharynx/larynx/oral cavity; hazard ratio [HR], 0.457; p=0.001), tumor size of RSPHNC (≥ 3 cm vs. < 3 cm; HR, 2.119; p=0.001), interval between RT courses (≥ 24 months vs. < 24 months; HR, 0.460; p < 0.001), and salvage surgery (yes vs. no; HR, 0.586; p=0.023) were confirmed as independent prognostic factors affecting OS. All results from the univariate and multivariate Cox regression analyses related to OS are shown in Table 2.

Local progression within the reirradiation field was developed in 50 patients (42.4%). The median time to local failure and 2-year LC rate were 28.9 months (range, 8.23 to 49.57 months) and 53.5%, respectively (Fig. 1). Both univariate and multivariate Cox regression models revealed that the interval between RT courses (p=0.078 and p=0.011, respectively) and performance of salvage surgery for RSPHNC (p=0.026 and p=0.042, respectively) were significant prognostic factors associated with LC (Table 2). Fig. 3A and Fig. 3B show the Kaplan-Meier LC curve according to the interval between RT courses (p=0.074) and performance of salvage surgery (p=0.023), respectively.

3. Survival validation according to MIRI RPA

We classified the patients into three prognostic classes according to the time interval between RT courses (< 2 years vs. ≥ 2 years), resectability (resected vs. unresected), and organ dysfunction (yes vs. no), as follows: those with interval > 2 years between RT courses with resected tumors (class I, n=25), those with interval > 2 years between RT courses with unresected tumors or with interval ≤ 2 years between RT courses without organ dysfunction (class II, n=89), and those with interval ≤ 2 years between RT courses with organ dysfunction (class III, n=4). The 2-year OS of each RPA class was 65.5% in class I, 38.0% in class II, and 25.0% in class III and was statistically significant (p=0.001) (Fig. 2D).

4. Toxicity

During IMRT-based reirradiation, no severe acute toxicity was recorded. At a median of 18.5 months after retreatment, grade ≥ 3 toxicity developed in 10 patients (8.5%), which consisted of grade 3 mucositis (n=2), interorgan fistula (n=4), dysphagia (n=2), and osteoradionecrosis (n=1) and grade 5 carotid blowout (n=1). With respect to organ dysfunction, 6 patients (5.1%) were tracheostomy-dependent, while 5 patients (4.2%) were feeding tube-dependent (Table 3).

Discussion

Our multi-center cohort study showed a 2-year OS of 43.1% and a 2-year LC of 53.5% after IMRT-based reirradiation for RSPHNC. The RSPHNC patients with small size tumors, a resectable status, and long interval between RT courses had a significantly better survival than their counterparts. We also validated the MIRI RPA classification by showing that RPA class I had a higher OS than class II or III. Regarding LC, we identified the independent impact of the interval between RT courses and performance of salvage surgery.

Previously published literature on IMRT for HNC reported that IMRT provides better oncologic outcomes and less toxicities than conventional RT [14,15]. Extending that view-point for RSPHNC patients, survival after IMRT-based reirradiation showed an improvement compared to conventional conformal reirradiation. The landmark prospective reirradiation trials in the pre-IMRT era including RTOG 9610 [16] and RTOG 9911 [17] reported that the 2-year OS ranged from 15% to 25% in patients who did not undergo salvage surgery. On the contrary, the MIRI group representatively showed an OS rate of 40% at 2 years following reirradiation of HNC in the IMRT era, which was 45% for postoperative patients and 36% for definitive patients [13]. Additionally, the Italy head and neck working group reported excellent outcomes of 44% OS at 5-year after reirradiation using advanced RT [18]. Of note, the current study showed that OS at 2 years was 43%, which was consistent with the abovementioned studies involving IMRT-based reirradiation. The favorable OS in our study could have resulted not only from this modern advanced RT technique but also from the high proportion of patients in RPA class I and II (96%), those who underwent salvage surgery (41%), those with a longer interval RT course application (56%), and those with no organ dysfunction at reirradiation (93%).

Specifically, our data supported that salvage surgery in conjunction with IMRT reirradiation for RSPHNC improved OS and LC [13,19]. Surgical resection of RSPHNC could be an important factor considering that RSPHNC was generated from radioresistant clonogens after initial chemoradiation [20,21]. Finally, removing macroscopic tumors is a way to enhance retreatment effectiveness owing to the limited dose of IMRT-based reirradiation for gross tumors since the adjacent organ around the tumor was already irradiated with a high dose during previous RT. It was suggested that when patients with RSPHNC expected medically operable and convincing problem, salvage surgery should be encouraged cautiously. The higher LC and OS were the result of the longer interval between RT courses. The appropriate time interval between RT treatments for performing reirradiation is not established, although it depends on the relation between previous the irradiated dose to organs at risk and its tolerance dose associated with normal tissue damage repair [22,23]. Previous studies reported that a longer interval from the previous RT course contributed to improved outcomes [13,21,24,25]. This was explained by the fact that, the longer the interval between RT treatments, the greater the likelihood of LC and the lesser the aggressiveness of recurrent disease. It is noteworthy that in our patient population, organ dysfunction was not a part of prognostic factors affecting OS since we had only 6.8% of all patients with organ dysfunction. It shows that there was a bias in patient selection for reirradiation at each institution. It could be presumed that a patient without organ dysfunction was selected for retreatment with IMRT-based reirradiation.

We validated the MIRI RPA classification for the whole patients’ population. The RPA classification differentiated the survival between class I and II/II. This difference was statistically significant. MIRI RPA class I cohort (66%) had a superior 2-year OS than class II and III (38% and 25%, respectively) cohorts. MIRI RPA class I might be the ideal subgroup who should undergo the active salvage treatment including IMRT reirradiation and/or surgical resection [13]. We found that the proposed RPA model might be applicable for our RSPHNC patient population and may help in patient selection for retreatment.

Reirradiation for RSPHNC is a challenging issue owing to an increased risk of severe toxicities including fatality [23]. The rate of severe and fatal late toxicity in these cohorts was 8.5% and 0.8%, respectively, whereas previous prospective studies reported the severe toxicity ranging from 22% to 34% and fatality rates of 3.6% to 7.6%, respectively [16,17]. The amelioration of safety was likely attributed to not only the intensity-modulated technique, but also the conservative patient selection criteria of each institution prior to embarking the reirradiation course. The MIRI Collaborative group reported that in the modern reirradiation era, the risk of progression or death (64%) is four times the incidence of severe late toxicity following reirradiation (17%) [26]. Such risk of late toxicity was more dependent on patient or disease factors than treatment factors. This implied that future research related to patient selection benefiting from reirradiation is needed to elicit the effectiveness of reirradiation using modern technology including IMRT.

This current study has many limitations. The dominant weakness is in its retrospective nature and a heterogeneous population from multi-centers. Our cohort had various features in terms of patient selection and treatment characteristics according to the physician’s discretion. Further, other limitations were the small number of patients from each center, which originated from the restriction of the cohort enrollment period, and the inherent limitations of IMRT. We did not identify the prognostic impact of human papillomavirus (HPV) in patients [27], especially those with oropharyngeal cancer undergoing reirradiation due to the availability of the HPV status of only 10 patients.

In conclusion, our multi-institutional study showed that IMRT-based reirradiation with a median dose of 60 Gy contributed to increased OS for patients with RSPHNC and had acceptable complications. Given the restricted salvage options, it could be considered an effective treatment for RSPHNC patients, especially those with small resectable tumors and a long interval between RT courses. Additionally, our cohort confirmed the prognostic validity of the survival rate of the MIRI RPA classification.

Electronic Supplementary Material

Supplementary materials are available at Cancer Research and Treatment website (https://www.e-crt.org).

S1 Table.

Baseline characteristics according to institution (7 institutions, n=118)

crt-2020-310-suppl.pdf

NOTES

Conflicts of interest relevant to this article was not reported.

Acknowledgements

This work was supported by Inha University Hospital Research Grant and the National Research Foundation of Korea (NRF) grant funded by the Korean government (MISP) under NRF-2014R1-A5A2009392.

Fig. 1.

Kaplan-Meier curve of overall survival and local control rates.

Fig. 2.

Kaplan-Meier curve of overall survival rate according to primary subsite (A), tumor size of recurrent or second primary tumor (B), interval between radiotherapy (RT) courses (C), salvage surgery (D), and recursive partitioning analysis (RPA) classes defined by the Multi-Institution Reirradiation Collaborative (E).

Fig. 3.

Kaplan-Meier curve of local control rate according to interval between radiotherapy (RT) courses (A) and salvage surgery (B).

Table 1.

Baseline characteristics

Variable	Total (n=118)
Initial presentation
Age, median (range, yr)	56 (20-83)
Sex
Male	92 (78.0)
Female	26 (22.0)
ECOG PS
0-1	110 (93.2)
2-3	8 (6.8)
Primary subsite
Nasopharynx	30 (25.4)
Oropharynx	15 (12.7)
Oral cavity	9 (7.6)
Paranasal sinus/Nasal cavity	23 (19.5)
Hypopharynx/Larynx	30 (25.4)
Other (SG, UP)	11 (9.3)
Histology
SCC	95 (80.5)
Non-SCC	23 (19.5)
Stage
I/II	31 (26.3)
III	16 (13.6)
IV	66 (55.9)
Unevaluable	5 (4.2)
Initial treatment
Treatment modality
Definitive RT/CRT	52 (44.1)
Surgery±PORT/CRT	48 (40.7)
Induction CTx+Definitive RT/CRT	13 (11.0)
Induction CTx+Surgery±PORT/CRT	3 (2.5)
Preoperative RT/CRT+Surgery	2 (1.6)
Initial RT total dose, median (range, Gy)	66.0 (40.0-78.6)
Initial RT fractional dose, median (range, Gy)	2.0 (1.2-2.5)
Second presentation
Age, median (range, yr)	59 (20-90)
< 60	63 (53.4)
≥ 60	55 (46.6)
ECOG PS
0-1	105.0 (89.0)
2-3	13.0 (11.0)
Presentation type
Recurrent	109 (92.4)
SP	9 (7.6)
rStage
rT0Nany	25 (21.2)
rT1Nany	13 (11.0)
rT2Nany	11 (9.3)
rT3Nany	19 (16.1)
rT4Nany	50 (42.4)
Failure type
Local failure	74 (62.7)
Regional failure	24 (20.3)
Locoregional failure	20 (16.9)
Recurrent or SP tumor size (cm)
Median, range	3.0 (0.5-11.0)
< 3	54 (45.8)
≥ 3	64 (54.2)
No. of recurrent or SP tumor
1	72 (61.0)
≥ 2	46 (39.0)
Pre-existing organ dysfunction
No	110 (93.2)
Yes^a)	8 (6.8)
RPA class^b)
Class I	25 (21.2)
Class II	89 (75.4)
Class III	4 (3.4)
Second treatment
Salvage surgery
No	70 (59.3)
Yes^c)	48 (40.7)
Chemotherapy
No	32 (27.1)
Yes	86 (72.9)
Reirradiation total dose (Gy)
Median (range)	59.4 (36.0-75.0)
< 60	60 (50.8)
≥ 60	58 (49.2)
Reirradiation fractional dose, median (range, Gy)	2.1 (1.8-4.0)
Treatment volume of reirradiation^d)
Focal field	100 (84.7)
Radical field	18 (15.3)
Cumulative RT dose, median (range, Gy)	124.9 (90.0-146.3)
Interval between RT courses (mo)
Median (range)	29.4 (2.6-293.4)
< 24	52 (44.1)
≥ 24	66 (55.9)

ECOG PS, Eastern Cooperative Oncology Group performance status; SG, salivary gland; UP, unknown primary; SCC, squamous cell carcinoma; RT, radiotherapy; CRT, chemoradiotherapy; PORT, postoperative radiotherapy; CTx, chemotherapy; SP, second primary; rStage, recurrent tumor and nodal stage; RPA, recursive partitioning analysis.

^a) Tracheostomy (n=6, 5.2%) or feeding tube dependence (n=2, 1.6%) prior to re-irradiation,

^b) Prognostic groups associated with overall survival according to RPA defined by the Multi-Institution Reirradiation (MIRI) Collaborative,

^c) Salvage surgery was performed in R0 resection for 29 patients and R1 resection for 19 patients,

^d) Focal field included the gross tumor or surgical bed plus margin of 0.5-1.0 cm, whereas radical field encompassed the gross tumor or surgical bed with elective high risk area plus margin of 0.5-1.0 cm.

Table 2.

Univariate and multivariate analysis affecting LC within reirradiation field and OS

Variable		OS				LC
		UVA		MVA^a)		UVA		MVA^a)
		HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value
Age at reirradiation (yr)
	< 60	Reference	0.089	-	-	Reference	0.494	-	-
	≥ 60	1.438 (0.947-2.183)		-		1.214 (0.696-2.118)		-
Sex
	Male	Reference	0.673	-	-	Reference	0.538	Reference	0.087
	Female	0.897 (0.540-1.490)		-		1.227 (0.641-2.348)		1.845 (0.915-3.722)
Histology
	SCC	Reference	0.137	-	-	Reference	0.851	-	-
	Non-SCC	0.655 (0.375-1.144)		-		0.936 (0.467-1.873)		-
Primary subsite
	Hypopharynx/Larynx/Oral cavity	Reference	0.001	Reference	0.001	Reference	0.403	-	-
	Non-hypopharynx/Larynx/Oral cavity	0.463 (0.298-0.722)		0.457 (0.294-0.711)		0.762 (0.403-1.440)
Presentation type
	Recurrent	Reference	0.068	-	-	Reference	0.550	-	-
	Second primary	0.429 (0.173-1.063)		-		0.730 (0.260-2.048)		-
Failure type
	Local failure	Reference	0.629	-	-	Reference	0.295	Reference	0.231
	Regional failure	1.129 (0.663-1.924)	0.654	-	-	0.804 (0.369-1.750)	0.582	0.669 (0.285-1.570)	0.356
	Locoregional failure	1.305 (0.747-2.280)	0.350	-	-	1.578 (0.792-3.144)	0.195	1.603 (0.670-3.834)	0.289
Recurrent or SP tumor size (cm)
	< 3	Reference	0.001	Reference	0.001	Reference	0.204	-	-
	≥ 3	2.213 (1.377-3.275)		2.119 (1.345-3.339)		1.444 (0.819-2.545)		-
No. of recurrent or SP tumors
	1	Reference	0.043	-	-	Reference	0.362	-	-
	≥ 2	1.542 (1.013-2.346)		-		1.302 (0.738-2.297)		-
Organ dysfunction
	No	Reference	0.110	-	-	Reference	0.649	-	-
	Yes	1.887 (0.866-4.111)		-		0.719 (0.173-2.978)		-
Interval between RT courses (mo)
	< 24	Reference	0.008	Reference	< 0.001	Reference	0.078	Reference	0.011
	≥ 24	0.569 (0.375-0.865)		0.460 (0.300-0.705)		0.605 (0.346-1.057)		0.458 (0.250-0.837)
Reirradiation dose (Gy)
	< 60	Reference	0.815	-	-	Reference	0.965	-	-
	≥ 60	0.952 (0.628-1.443)		-		0.988 (0.567-1.720)		-
Treatment volume of reirradiation
	Focal field	Reference	0.616	-	-	Reference	0.146	Reference	0.063
	Radical field	0.864 (0.488-1.530)		-		0.504 (0.200-1.270)		0.394 (0.148-1.050)
Salvage surgery
	No	Reference	0.002	Reference	0.023	Reference	0.026	Reference	0.042
	Yes	0.497 (0.319-0.776)		0.586 (0.369-0.930)		0.506 (0.278-0.922)		0.525 (0.282-0.977)
Chemotherapy
	No	Reference	0.159	-	-	Reference	0.902	-	-
	Yes	1.424 (0.871-2.327)		-		1.040 (0.561-1.929)		-
MIRI RPA class^b)
	Class I	Reference	0.003	-	-	-	-	-	-
	Class II	2.629 (1.419-4.869)	0.002	-	-	-	-	-	-
	Class III	5.259 (1.677-16.488)	0.004	-	-	-	-	-	-

LC, local control; OS, overall survival; UVA, univariate analysis; MVA, multivariate analysis; HR, hazards ratio; CI, confidence interval; SCC, squamous cell carcinoma; SP, second primary; RT, radiotherapy; RPA, recursive partitioning analysis.

^a) All variables (except RPA class) were analyzed using the binary Cox regression model with a backward stepwise method if p ≤ 0.10, and they were removed when p > 0.10,

^b) Prognostic groups defined according to RPA reported by the Multi-Institution Reirradiation (MIRI) Collaborative.

Table 3.

Incidence of severe toxicity and organ dysfunction status following IMRT-based reirradiation

Variable	No. (%)
Grade ≥ 3 toxicity	10 (8.5)
Grade 3
Mucositis	2 (1.7)
Interorgan fistula	4 (3.4)
Dysphagia	2 (1.7)
Osteoradionecrosis	1 (0.8)
Grade 5
Carotid blowout	1 (0.8)
Organ dysfunction	11 (9.3)
Tracheostomy	6 (5.1)
Feeding tube dependence	5 (4.2)

IMRT, intensity-modulated radiotherapy.

REFERENCES

1. Chao KS, Ozyigit G, Tran BN, Cengiz M, Dempsey JF, Low DA. Patterns of failure in patients receiving definitive and postoperative IMRT for head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2003;55:312–21. Article PubMed
2. Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol. 2014;32:2940–50. Article PubMed PMC
3. Beitler JJ, Zhang Q, Fu KK, Trotti A, Spencer SA, Jones CU, et al. Final results of local-regional control and late toxicity of RTOG 9003: a randomized trial of altered fractionation radiation for locally advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 2014;89:13–20. Article PubMed PMC
4. Wong LY, Wei WI, Lam LK, Yuen AP. Salvage of recurrent head and neck squamous cell carcinoma after primary curative surgery. Head Neck. 2003;25:953–9. Article PubMed
5. Goodwin WJ Jr. Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means? Laryngoscope. 2000;110:1–18. Article
6. Cacicedo J, Navarro A, Alongi F, Gomez de Iturriaga A, Del Hoyo O, Boveda E, et al. The role of re-irradiation of secondary and recurrent head and neck carcinomas: is it a potentially curative treatment? A practical approach. Cancer Treat Rev. 2014;40:178–89. Article PubMed
7. Intensity Modulated Radiation Therapy Collaborative Working Group. Intensity-modulated radiotherapy: current status and issues of interest. Int J Radiat Oncol Biol Phys. 2001;51:880–914. Article PubMed
8. Puri DR, Chou W, Lee N. Intensity-modulated radiation therapy in head and neck cancers: dosimetric advantages and update of clinical results. Am J Clin Oncol. 2005;28:415–23. Article PubMed
9. Lee N, Puri DR, Blanco AI, Chao KS. Intensity-modulated radiation therapy in head and neck cancers: an update. Head Neck. 2007;29:387–400. Article PubMed
10. Ho JC, Phan J. Reirradiation of head and neck cancer using modern highly conformal techniques. Head Neck. 2018;40:2078–93. Article PubMed
11. Chen AM, Phillips TL, Lee NY. Practical considerations in the re-irradiation of recurrent and second primary head-and-neck cancer: who, why, how, and how much? Int J Radiat Oncol Biol Phys. 2011;81:1211–9. Article PubMed
12. Kim YS. Reirradiation of head and neck cancer in the era of intensity-modulated radiotherapy: patient selection, practical aspects, and current evidence. Radiat Oncol J. 2017;35:1–15. Article PubMed PMC PDF
13. Ward MC, Riaz N, Caudell JJ, Dunlap NE, Isrow D, Zakem SJ, et al. Refining patient selection for reirradiation of head and neck squamous carcinoma in the IMRT era: a multi-institution cohort study by the MIRI collaborative. Int J Radiat Oncol Biol Phys. 2018;100:586–94. Article PubMed
14. Toledano I, Graff P, Serre A, Boisselier P, Bensadoun RJ, Ortholan C, et al. Intensity-modulated radiotherapy in head and neck cancer: results of the prospective study GORTEC 2004-03. Radiother Oncol. 2012;103:57–62. Article PubMed
15. Zhang B, Mo Z, Du W, Wang Y, Liu L, Wei Y. Intensity-modulated radiation therapy versus 2D-RT or 3D-CRT for the treatment of nasopharyngeal carcinoma: a systematic review and meta-analysis. Oral Oncol. 2015;51:1041–6. Article PubMed
16. Spencer SA, Harris J, Wheeler RH, Machtay M, Schultz C, Spanos W, et al. Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck. 2008;30:281–8. Article PubMed
17. Langer CJ, Harris J, Horwitz EM, Nicolaou N, Kies M, Curran W, et al. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. J Clin Oncol. 2007;25:4800–5. Article PubMed
18. Orlandi E, Bonomo P, Ferella L, D’Angelo E, Maddalo M, Alterio D, et al. Long-term outcome of re-irradiation for recurrent or second primary head and neck cancer: a multi-institutional study of AIRO-Head and Neck working group. Head Neck. 2019;41:3684–92. Article PubMed
19. Riaz N, Hong JC, Sherman EJ, Morris L, Fury M, Ganly I, et al. A nomogram to predict loco-regional control after re-irradiation for head and neck cancer. Radiother Oncol. 2014;111:382–7. Article PubMed PMC
20. Weichselbaum RR, Beckett MA, Schwartz JL, Dritschilo A. Radioresistant tumor cells are present in head and neck carcinomas that recur after radiotherapy. Int J Radiat Oncol Biol Phys. 1988;15:575–9. Article PubMed
21. Yard B, Chie EK, Adams DJ, Peacock C, Abazeed ME. Radiotherapy in the era of precision medicine. Semin Radiat Oncol. 2015;25:227–36. Article PubMed
22. Van der Schueren E, Van den Bogaert W, Vanuytsel L, Van Limbergen E. Radiotherapy by multiple fractions per day (MFD) in head and neck cancer: acute reactions of skin and mucosa. Int J Radiat Oncol Biol Phys. 1990;19:301–11. Article PubMed
23. Hoebers F, Heemsbergen W, Moor S, Lopez M, Klop M, Tesselaar M, et al. Reirradiation for head-and-neck cancer: delicate balance between effectiveness and toxicity. Int J Radiat Oncol Biol Phys. 2011;81:e111–8. Article PubMed
24. Velez MA, Veruttipong D, Wang PC, Chin R, Beron P, Abemayor E, et al. Re-irradiation for recurrent and second primary cancers of the head and neck. Oral Oncol. 2017;67:46–51. Article PubMed
25. Chopra S, Gupta T, Agarwal JP, Budrukkar A, Ghosh-Laskar S, Dinshaw K. Re-irradiation in the management of isolated neck recurrences: current status and recommendations. Radiother Oncol. 2006;81:1–8. Article PubMed
26. Ward MC, Lee NY, Caudell JJ, Zajichek A, Awan MJ, Koyfman SA, et al. A competing risk nomogram to predict severe late toxicity after modern re-irradiation for squamous carcinoma of the head and neck. Oral Oncol. 2019;90:80–6. Article PubMed
27. Velez MA, Wang PC, Hsu S, Chin R, Beron P, Abemayor E, et al. Prognostic significance of HPV status in the re-irradiation of recurrent and second primary cancers of the head and neck. Am J Otolaryngol. 2018;39:257–60. Article PubMed

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Re-irradiation for head and neck cancer: outcome and toxicity analysis using a prospective single institution database
Chiara Scolari, André Buchali, Achim Franzen, Robert Förster, Paul Windisch, Stephan Bodis, Daniel R. Zwahlen, Christina Schröder
Frontiers in Oncology.2023;[Epub] CrossRef
Double trouble: A cohort study of re-irradiation and laryngectomy – Severity of and risk for pharyngocutaneous fistula
Jeffrey M. Weinberger, Narmeen abd el Qadir, Nir Hirshoren
Oral Oncology.2022; 134: 106069. CrossRef
Current radiotherapy for recurrent head and neck cancer in the modern era: a state-of-the-art review
Yue Li, Yuliang Jiang, Bin Qiu, Haitao Sun, Junjie Wang
Journal of Translational Medicine.2022;[Epub] CrossRef
Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Big and Intriguing Challenge Which May Be Resolved by Integrated Treatments Combining Locoregional and Systemic Therapies
Franco Ionna, Paolo Bossi, Agostino Guida, Andrea Alberti, Paolo Muto, Giovanni Salzano, Alessandro Ottaiano, Fabio Maglitto, Davide Leopardo, Marco De Felice, Francesco Longo, Salvatore Tafuto, Giuseppina Della Vittoria Scarpati, Francesco Perri
Cancers.2021; 13(10): 2371. CrossRef
Re-irradiation for recurrent or second primary head and neck cancer
Hye In Lee, Jin Ho Kim, Soon-Hyun Ahn, Eun-Jae Chung, Bhumsuk Keam, Keun-Yong Eom, Woo-Jin Jeong, Ji-Won Kim, Chan Woo Wee, Hong-Gyun Wu
Radiation Oncology Journal.2021; 39(4): 279. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Intensity-Modulated Radiotherapy-Based Reirradiation for Head and Neck Cancer: A Multi-institutional Study by Korean Radiation Oncology Group (KROG 1707)

Cancer Res Treat. 2020;52(4):1031-1040. Published online July 7, 2020

DOI: https://doi.org/10.4143/crt.2020.310

XML Download

Abstract
Introduction
Materials and Methods
Results
Discussion
Electronic Supplementary Material
NOTES
REFERENCES

Intensity-Modulated Radiotherapy-Based Reirradiation for Head and Neck Cancer: A Multi-institutional Study by Korean Radiation Oncology Group (KROG 1707)

Fig. 1. Kaplan-Meier curve of overall survival and local control rates.

Fig. 2. Kaplan-Meier curve of overall survival rate according to primary subsite (A), tumor size of recurrent or second primary tumor (B), interval between radiotherapy (RT) courses (C), salvage surgery (D), and recursive partitioning analysis (RPA) classes defined by the Multi-Institution Reirradiation Collaborative (E).

Fig. 3. Kaplan-Meier curve of local control rate according to interval between radiotherapy (RT) courses (A) and salvage surgery (B).

Fig. 1.

Fig. 2.

Fig. 3.

Intensity-Modulated Radiotherapy-Based Reirradiation for Head and Neck Cancer: A Multi-institutional Study by Korean Radiation Oncology Group (KROG 1707)

Variable	Total (n=118)
Initial presentation
Age, median (range, yr)	56 (20-83)
Sex
Male	92 (78.0)
Female	26 (22.0)
ECOG PS
0-1	110 (93.2)
2-3	8 (6.8)
Primary subsite
Nasopharynx	30 (25.4)
Oropharynx	15 (12.7)
Oral cavity	9 (7.6)
Paranasal sinus/Nasal cavity	23 (19.5)
Hypopharynx/Larynx	30 (25.4)
Other (SG, UP)	11 (9.3)
Histology
SCC	95 (80.5)
Non-SCC	23 (19.5)
Stage
I/II	31 (26.3)
III	16 (13.6)
IV	66 (55.9)
Unevaluable	5 (4.2)
Initial treatment
Treatment modality
Definitive RT/CRT	52 (44.1)
Surgery±PORT/CRT	48 (40.7)
Induction CTx+Definitive RT/CRT	13 (11.0)
Induction CTx+Surgery±PORT/CRT	3 (2.5)
Preoperative RT/CRT+Surgery	2 (1.6)
Initial RT total dose, median (range, Gy)	66.0 (40.0-78.6)
Initial RT fractional dose, median (range, Gy)	2.0 (1.2-2.5)
Second presentation
Age, median (range, yr)	59 (20-90)
< 60	63 (53.4)
≥ 60	55 (46.6)
ECOG PS
0-1	105.0 (89.0)
2-3	13.0 (11.0)
Presentation type
Recurrent	109 (92.4)
SP	9 (7.6)
rStage
rT0Nany	25 (21.2)
rT1Nany	13 (11.0)
rT2Nany	11 (9.3)
rT3Nany	19 (16.1)
rT4Nany	50 (42.4)
Failure type
Local failure	74 (62.7)
Regional failure	24 (20.3)
Locoregional failure	20 (16.9)
Recurrent or SP tumor size (cm)
Median, range	3.0 (0.5-11.0)
< 3	54 (45.8)
≥ 3	64 (54.2)
No. of recurrent or SP tumor
1	72 (61.0)
≥ 2	46 (39.0)
Pre-existing organ dysfunction
No	110 (93.2)
Yes^a)	8 (6.8)
RPA class^b)
Class I	25 (21.2)
Class II	89 (75.4)
Class III	4 (3.4)
Second treatment
Salvage surgery
No	70 (59.3)
Yes^c)	48 (40.7)
Chemotherapy
No	32 (27.1)
Yes	86 (72.9)
Reirradiation total dose (Gy)
Median (range)	59.4 (36.0-75.0)
< 60	60 (50.8)
≥ 60	58 (49.2)
Reirradiation fractional dose, median (range, Gy)	2.1 (1.8-4.0)
Treatment volume of reirradiation^d)
Focal field	100 (84.7)
Radical field	18 (15.3)
Cumulative RT dose, median (range, Gy)	124.9 (90.0-146.3)
Interval between RT courses (mo)
Median (range)	29.4 (2.6-293.4)
< 24	52 (44.1)
≥ 24	66 (55.9)

Variable		OS				LC
		UVA		MVA^a)		UVA		MVA^a)
		HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value
Age at reirradiation (yr)
	< 60	Reference	0.089	-	-	Reference	0.494	-	-
	≥ 60	1.438 (0.947-2.183)		-		1.214 (0.696-2.118)		-
Sex
	Male	Reference	0.673	-	-	Reference	0.538	Reference	0.087
	Female	0.897 (0.540-1.490)		-		1.227 (0.641-2.348)		1.845 (0.915-3.722)
Histology
	SCC	Reference	0.137	-	-	Reference	0.851	-	-
	Non-SCC	0.655 (0.375-1.144)		-		0.936 (0.467-1.873)		-
Primary subsite
	Hypopharynx/Larynx/Oral cavity	Reference	0.001	Reference	0.001	Reference	0.403	-	-
	Non-hypopharynx/Larynx/Oral cavity	0.463 (0.298-0.722)		0.457 (0.294-0.711)		0.762 (0.403-1.440)
Presentation type
	Recurrent	Reference	0.068	-	-	Reference	0.550	-	-
	Second primary	0.429 (0.173-1.063)		-		0.730 (0.260-2.048)		-
Failure type
	Local failure	Reference	0.629	-	-	Reference	0.295	Reference	0.231
	Regional failure	1.129 (0.663-1.924)	0.654	-	-	0.804 (0.369-1.750)	0.582	0.669 (0.285-1.570)	0.356
	Locoregional failure	1.305 (0.747-2.280)	0.350	-	-	1.578 (0.792-3.144)	0.195	1.603 (0.670-3.834)	0.289
Recurrent or SP tumor size (cm)
	< 3	Reference	0.001	Reference	0.001	Reference	0.204	-	-
	≥ 3	2.213 (1.377-3.275)		2.119 (1.345-3.339)		1.444 (0.819-2.545)		-
No. of recurrent or SP tumors
	1	Reference	0.043	-	-	Reference	0.362	-	-
	≥ 2	1.542 (1.013-2.346)		-		1.302 (0.738-2.297)		-
Organ dysfunction
	No	Reference	0.110	-	-	Reference	0.649	-	-
	Yes	1.887 (0.866-4.111)		-		0.719 (0.173-2.978)		-
Interval between RT courses (mo)
	< 24	Reference	0.008	Reference	< 0.001	Reference	0.078	Reference	0.011
	≥ 24	0.569 (0.375-0.865)		0.460 (0.300-0.705)		0.605 (0.346-1.057)		0.458 (0.250-0.837)
Reirradiation dose (Gy)
	< 60	Reference	0.815	-	-	Reference	0.965	-	-
	≥ 60	0.952 (0.628-1.443)		-		0.988 (0.567-1.720)		-
Treatment volume of reirradiation
	Focal field	Reference	0.616	-	-	Reference	0.146	Reference	0.063
	Radical field	0.864 (0.488-1.530)		-		0.504 (0.200-1.270)		0.394 (0.148-1.050)
Salvage surgery
	No	Reference	0.002	Reference	0.023	Reference	0.026	Reference	0.042
	Yes	0.497 (0.319-0.776)		0.586 (0.369-0.930)		0.506 (0.278-0.922)		0.525 (0.282-0.977)
Chemotherapy
	No	Reference	0.159	-	-	Reference	0.902	-	-
	Yes	1.424 (0.871-2.327)		-		1.040 (0.561-1.929)		-
MIRI RPA class^b)
	Class I	Reference	0.003	-	-	-	-	-	-
	Class II	2.629 (1.419-4.869)	0.002	-	-	-	-	-	-
	Class III	5.259 (1.677-16.488)	0.004	-	-	-	-	-	-

Variable	No. (%)
Grade ≥ 3 toxicity	10 (8.5)
Grade 3
Mucositis	2 (1.7)
Interorgan fistula	4 (3.4)
Dysphagia	2 (1.7)
Osteoradionecrosis	1 (0.8)
Grade 5
Carotid blowout	1 (0.8)
Organ dysfunction	11 (9.3)
Tracheostomy	6 (5.1)
Feeding tube dependence	5 (4.2)

Table 1. Baseline characteristics

Tracheostomy (n=6, 5.2%) or feeding tube dependence (n=2, 1.6%) prior to re-irradiation,

Prognostic groups associated with overall survival according to RPA defined by the Multi-Institution Reirradiation (MIRI) Collaborative,

Salvage surgery was performed in R0 resection for 29 patients and R1 resection for 19 patients,

Focal field included the gross tumor or surgical bed plus margin of 0.5-1.0 cm, whereas radical field encompassed the gross tumor or surgical bed with elective high risk area plus margin of 0.5-1.0 cm.

Table 2. Univariate and multivariate analysis affecting LC within reirradiation field and OS

All variables (except RPA class) were analyzed using the binary Cox regression model with a backward stepwise method if p ≤ 0.10, and they were removed when p > 0.10,

Prognostic groups defined according to RPA reported by the Multi-Institution Reirradiation (MIRI) Collaborative.

Table 3. Incidence of severe toxicity and organ dysfunction status following IMRT-based reirradiation

IMRT, intensity-modulated radiotherapy.